Patients See Thirty-Four Percent Drop in Heart Failures After Impairment Treatment
Patients with advanced heart failure experienced a 34% reduction in hospitalizations one year after receiving a specialized cardiac implant, HCPLive reported. The finding comes from a real-world analysis of Impulse Dynamics’ OPTIMIZER device and cardiac contractility modulation (CCM) therapy, presented at the Heart Failure Society of America Annual Scientific Meeting in Phoenix, Arizona.
Researchers tracked 530 patients who had paired baseline and one-year data out of 692 total participants enrolled between February 2020 and September 2025. The study examined outcomes for adults with New York Heart Association Class 3 heart failure symptoms and a left ventricular ejection fraction between 25% and 45%. Among the studied cohort, the mean age was 67.3 years, and 40.6% of the patients had atrial fibrillation. Concurrent medication use among the group included beta blockers in 94% of patients, angiotensin receptor-neprilysin inhibitors in 56.6%, and SGLT2 inhibitors in 35.7%.
Discover how cardiac contractility modulation (CCM) therapy is advancing heart failure management and addressing unmet needs in patients who remain symptomatic despite guideline-directed medical therapy.
Hospitalizations Fall While Functional Status Improves
The rate of heart failure hospitalizations dropped from 152 events before the CCM implantation down to 91 events after one year, marking a statistically significant decline. Functional capacity also showed widespread stabilization or progress across the cohort.
Clinical metrics demonstrated that 97% of patients experienced either an improved or stabilized New York Heart Association functional class at the one-year mark. Specifically, 68% of the group moved into a better functional class. Quality of life assessments, measured by the Minnesota Living with Heart Failure Questionnaire, revealed a clinically meaningful improvement of at least five points in 70% of the participants. Meanwhile, N-terminal pro-B-type natriuretic peptide levels remained stable from baseline to one year, though researchers identified a predictive link between levels exceeding 1,000 pg/mL and long-term mortality.
Three-Year Follow-Ups Track Objective Data
Investigators acknowledged limitations in the study design, including its non-randomized structure and lack of a control group. However, the team concluded that the results accurately reflect real-world clinical practice under contemporary guideline-directed medical therapy.
Moneeb Kahwash, a study investigator who reported disclosures with device makers including Impulse Dynamics, Medtronic, and Boston Scientific, noted that the evaluation is continuing past the initial milestone.
“We’re excited that this trial is not going to stop at 1 year,” Kahwash said. “We’re following these patients for 3 years, so we’re going to have long-term follow-ups coming in.”
Future analysis aims to connect these clinical signals with objective yearly measurements, such as echocardiographic data and extended N-terminal pro-B-type natriuretic peptide tracking, according to the study registry protocol.